Perspective Therapeutics (CATX) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Perspective Therapeutics (CATX) over the past year, losing 1.7% versus a loss of 51.7%. Over five years, LFCR leads with a -32.8% price change compared with -66.1% for CATX. Perspective Therapeutics is the larger company by market cap ($247.7 million vs $241.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | LFCR |
|---|---|---|
| Share price | $2.17 | $6.38 |
| Market cap | $247.71M | $241.84M |
| 1-day change | -7.26% | -0.93% |
| YTD return | -21.09% | -22.00% |
| 1-year return | -51.67% | -1.69% |
| 5-year return | -66.09% | -32.84% |
| EPS (TTM) | $-1.33 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $128.87M |
| Revenue growth (YoY) | — | +0.47% |
| Net income (latest FY) | $-103.12M | $-38.72M |
| Gross margin | — | 31.27% |
| Operating margin | — | -13.38% |
| Net margin | — | -30.04% |
| 52-week high | $6.16 | $8.98 |
| 52-week low | $1.96 | $3.63 |
| Distance from 52-week high | -64.77% | -28.95% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +466.36% | -1.57% |
| Average volume | 1.58M | 330.83K |
| Shares outstanding | 114.15M | 37.91M |
| Employees | 163 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed CATX by 50.0 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
CATX vs LFCR FAQ
Which is bigger, Perspective Therapeutics or Lifecore Biomedical?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $247.71M compared with $241.84M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, CATX or LFCR?
LFCR returned -1.69% over the past 12 months, compared with -51.67% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.